Trial Profile
Immunogenicity and Safety of the Investigational Inactivated, Split-Virion Influenza Vaccine 15 microg Administered by the Intradermal Route in Comparison with the Intramuscular Reference Vaccine Vaxigrip in 50 to 59 Years old Adults.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Sanofi Pasteur
- 03 Apr 2022 Status changed from recruiting to completed.
- 02 Aug 2011 New trial record